We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Antisense battles small molecule for slice of rare lipid disorder market.
- Authors
Sinha, Gunjan
- Abstract
The article reports on the approval of the two lipid-lowering drugs, small-molecule Juxtapid (lomitapide) from Aegerion Pharmaceuticals and Kynamro (mipomersen) from Sanofi and Isis Pharmaceuticals, by the U.S. Food and Drug Administration (FDA). It states that the drugs are registered as treatment for rare disorder, homozygous familial hypercholesterolemia (FH). It adds that the approval of antisense drugs can boost investor confidence and provides opportunity to other antisense drugs.
- Subjects
DRUG approval; ANTILIPEMIC agents; AEGERION Pharmaceuticals Inc.; SANOFI-Aventis SA; IONIS Pharmaceuticals Inc.; UNITED States. Food &; Drug Administration; ANTISENSE drugs; HYPERCHOLESTEREMIA treatment
- Publication
Nature Biotechnology, 2013, Vol 31, Issue 3, p179
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0313-179